Stevanato Group (NYSE:STVN) Director William Federici Purchases 20,000 Shares of Stock

Stevanato Group S.p.A. (NYSE:STVN) Director William Federici purchased 20,000 shares of the firm’s stock in a transaction on Monday, November 9th. The stock was acquired at an average price of €13.72 per share, with a total value of €274,400.00. Following the completion of the purchase, the director owned 46,991 shares of the company’s stock, valued at €644,716.52. The trade was a 74.10% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Stevanato Group Price Performance

Shares of STVN stock opened at €14.33 on Friday. Stevanato Group S.p.A. has a fifty-two week low of €12.05 and a fifty-two week high of €24.01. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.19 and a current ratio of 1.73. The firm has a market capitalization of $4.34 billion, a price-to-earnings ratio of 24.70, a PEG ratio of 1.44 and a beta of 0.80. The stock’s 50-day simple moving average is €19.23 and its 200-day simple moving average is €17.92.

Stevanato Group (NYSE:STVN) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported €0.16 EPS for the quarter, missing the consensus estimate of €0.17 by (€0.01). The company had revenue of €326.06 million during the quarter. Stevanato Group had a net margin of 11.24% and a return on equity of 10.51%. As a group, equities analysts forecast that Stevanato Group S.p.A. will post 0.67 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. William Blair downgraded Stevanato Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 4th. Deutsche Bank assumed coverage on Stevanato Group in a report on Wednesday, October 7th. They issued a “hold” rating on the stock. Weiss Ratings upgraded Stevanato Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, August 27th. UBS Group reduced their price target on shares of Stevanato Group from $23.00 to $16.00 and set a “neutral” rating for the company in a research report on Wednesday, November 4th. Finally, Citigroup decreased their price objective on shares of Stevanato Group from $26.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, November 4th. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.

Institutional Investors Weigh In On Stevanato Group

Hedge funds and other institutional investors have recently made changes to their positions in the company. First Bank & Trust lifted its stake in shares of Stevanato Group by 3.4% in the 2nd quarter. First Bank & Trust now owns 18,417 shares of the company’s stock valued at $333,000 after purchasing an additional 603 shares during the period. Fifth Third Bancorp raised its holdings in Stevanato Group by 22.6% in the 1st quarter. Fifth Third Bancorp now owns 4,196 shares of the company’s stock worth $58,000 after purchasing an additional 773 shares during the period. PineStone Asset Management Inc. boosted its position in Stevanato Group by 8.4% during the third quarter. PineStone Asset Management Inc. now owns 41,335 shares of the company’s stock worth $867,000 after purchasing an additional 3,200 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new stake in shares of Stevanato Group in the second quarter valued at approximately $59,000. Finally, GW&K Investment Management LLC raised its stake in shares of Stevanato Group by 118.3% during the 3rd quarter. GW&K Investment Management LLC now owns 6,086 shares of the company’s stock worth $128,000 after buying an additional 3,298 shares during the period.

About Stevanato Group

Stevanato Group is an Italian provider of drug-containment and drug-delivery solutions for the pharmaceutical, biotechnology and diagnostic industries. Founded in 1949 by Giovanni Stevanato, the company began as a glassmaking business and has expanded into a global supplier of products and services for the life sciences sector. The company makes primary packaging for injectable medicines, including glass vials, cartridges, syringes and ampoules. Its offerings also include ready-to-use containers, as well as services such as product development, analytical testing and packaging support.